Literature DB >> 16575152

Peripheral antinociception by carbamazepine in an inflammatory mechanical hyperalgesia model in the rat: a new target for carbamazepine?

Sonja Vuckovic1, Maja Tomic, Radica Stepanovic-Petrovic, Nenad Ugresic, Milica Prostran, Bogdan Boskovic.   

Abstract

This study investigated whether carbamazepine could produce local peripheral antinociception in a rat model of inflammatory mechanical hyperalgesia, and whether adenosine receptors are involved. Carbamazepine (100-1000 nmol/paw) co-administrated with a pro-inflammatory compound, concanavalin A, into the hind paw caused a significant dose- and time-dependent anti-hyperalgesia. Coadministration of caffeine (250-1000 nmol/paw), a nonselective adenosine-receptor antagonist, as well as DPCPX (10-30 nmol/paw), a selective adenosine A(1)-receptor antagonist, with carbamazepine, significantly depressed its anti-hyperalgesic effect. Drugs injected into the contralateral hind paw did not produce significant effects. These results suggest that carbamazepine produces local peripheral anti-hyperalgesia via peripheral adenosine A(1) receptors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16575152     DOI: 10.1254/jphs.sce05003x

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  3 in total

Review 1.  Cannabinoids and Pain: New Insights From Old Molecules.

Authors:  Sonja Vučković; Dragana Srebro; Katarina Savić Vujović; Čedomir Vučetić; Milica Prostran
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

2.  Preliminarily Analysis of Carbamazepine (CBZ) C0 in Patients Visited Isfahan Epileptic Clinics.

Authors:  Zahra Tolou-Ghamari; Mohammad Reza Najafi; Jafar Mehavari Habibabadi; Mohmmad Zare
Journal:  Int J Prev Med       Date:  2013-05

3.  A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012.

Authors:  Zahra Tolou-Ghamari; Mohammad Zare; Jafar Mehvari Habibabadi; Mohammad Reza Najafi
Journal:  J Res Med Sci       Date:  2013-03       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.